COMMUNIQUÉS West-GlobeNewswire

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
15/10/2026
In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.” NRx was requested to prepare and submit labels with the proprietary name currently under review by FDA. NRx is [...]
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
15/10/2026
Leading Healthcare Investors, includ ing Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in [...]
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
15/10/2026
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results [...]
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
15/10/2026
New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization [...]
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
15/10/2026
Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial The Company has a statistical team who are doing periodic reviews of the unblinded data to [...]
ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant
15/10/2026
New patent allowances in South Korea, Mexico, New Zealand and the Philippines Further expand IP protection across BPD, ASD, aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE [...]
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
15/10/2026
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T [...]
Callio Therapeutics Wins Best New ADC Drug Developer at the 13th World ADC Awards, Presents Across Five Sessions at World ADC San Diego
15/10/2026
Callio leaders delivered three presentations and two panel discussions on dual-payload ADC resistance, manufacturability, linker design, and the path to next-generation ADCs SAN DIEGO, SEATTLE and SINGAPORE, Oct. 15, [...]
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
15/10/2026
Internally-derived candidate targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- [...]
Nema Health Expands Access to Specialized PTSD Treatment Through Evernorth Behavioral Health Network
15/10/2026
New in-network agreement makes evidence-based trauma treatment more accessible to eligible Cigna Healthcare and Evernorth members NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nema Health, a virtual specialty care [...]
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
15/10/2026
Initial Stage 1 data evaluating ven s obafusp alfa in IgAN expected by year-end 2026 Announces e xpansion cohort in patients with FSGS , with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, [...]
Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
15/10/2026
FDA-cleared BVA ™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care. Key Highlights: Commercial Acceleration: Daxor showcasing its [...]
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
15/10/2026
NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious [...]
PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES
15/10/2026
MINNEAPOLIS, MN, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV) (“PetVivo” or the “Company”), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo [...]
First Tracks Biotherapeutics Announces $200 Million Private Placement
15/10/2026
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
15/10/2026
Company remains on track to report interim results from Phase 2b cohort in 4Q 2026 NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing [...]
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
15/10/2026
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding [...]
Claris Biotherapeutics to Host Virtual KOL Event on Positive CSB-001 Data and the Unmet Need in Limbal Stem Cell Deficiency (LSCD)
15/10/2026
SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc., a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where limited or no [...]
Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026
15/10/2026
Dr. Megha Prasad to deliver podium presentation featuring Conavi’s hybrid IVUS–OCT imaging Abstract presentation on saline-based hybrid IVUS–OCT imaging Participation in two CRF Imaging Lab physician education sessions [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.